Gastrointestinal Cancer | Specialty

Dr. Mehta on the Evolution of Treatment in Gastric and GEJ Cancers

August 11th 2020

Rutika J. Mehta, MD, MPH, discusses how treatment has evolved in recent years for gastric and gastroesophageal junction cancers.

Dr. VanderWalde on Personalizing Therapy in Rectal Cancer

August 10th 2020

Noam VanderWalde, MD, MS, discusses the push toward personalizing therapy in rectal cancer.

Pancreatic Cancer Updates

August 10th 2020

Liver Cancer Updates

August 10th 2020

Gastric Cancer Updates

August 10th 2020

Colorectal Cancer Updates

August 10th 2020

Phase 3 OPTIMA Trial in HCC to Continue to Follow Patients for OS

August 4th 2020

Celsion Corporation will continue to follow patients with hepatocellular carcinoma enrolled on the phase 3 OPTIMA trial examining ThermoDox® in combination with radiofrequency ablation for overall survival.

Ripretinib Granted Priority Review in China for Advanced GIST

August 4th 2020

China’s National Medical Products Administration has granted priority review status to a new drug application for ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumor who received previous treatment with 3 or more kinase inhibitors, including imatinib.

Blood-Based Assay Could Soon Surface in Colorectal Cancer

August 4th 2020

Shai Friedland, MD, discusses the novel multimodal FirstSight test, which showed promise in identifying colorectal cancer, as well as precancerous polyps and advanced adenomas.

KEYNOTE-177 Cements Pembrolizumab as New Standard of Care in MSI-H/dMMR mCRC

August 4th 2020

Thierry Andre, MD, discusses the results of the KEYNOTE-177 trial in metastatic colorectal cancer.

Adding Celecoxib to FOLFOX Does Not Demonstrate DFS Benefit in Colon Cancer

August 4th 2020

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the addition of celecoxib to standard chemotherapy, stating that it did not significantly improve disease-free survival or overall survival in patients with colon cancer.

Dr. Kundranda on the Need for Novel Treatments in Pancreatic Ductal Adenocarcinoma

August 3rd 2020

Madappa Kundranda, MD, PhD, discusses the need ​to develop novel treatments in pancreatic ductal adenocarcinoma.

FDA Grants SM-88 Orphan Drug Status for Pancreatic Cancer

August 3rd 2020

The FDA granted an orphan drug designation to the oral investigational modified proprietary tyrosine derivative SM-88 as a treatment for patients with pancreatic cancer.

Ripretinib Approval Advances Recurrent GIST Paradigm

August 3rd 2020

Ripretinib has become the first therapy specifically approved for the fourth-line treatment of gastrointestinal stromal tumors, a clinical setting with an unmet medical need because of the poor prognosis of patients with progressive disease.

Making Up for Lost Time in GI Cancers

August 3rd 2020

Tanios S. Bekaii-Saab, MD, discusses how the field of gastrointestinal cancers is gaining ground with regard to the development of targeted and immunotherapy agents.

Progress Made in Pancreatic Cancer Allows for Personalized Approaches

August 3rd 2020

Syma Iqbal, MD, discusses the strategies used for the first-line treatment of patients with pancreatic cancer, options for later-line settings, and research efforts being made with targeted therapies.

El-Khoueiry Elucidates Recent Updates in the Rapidly Evolving HCC Treatment Paradigm

July 31st 2020

Anthony B. El-Khoueiry, MD, discusses the evolution of HCC treatment, paradigm-shifting trials, and where future research is headed.

Dr. Shah on Updated Results With Trastuzumab Deruxtecan in DESTINY-Gastric01

July 23rd 2020

Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.

Dr. Ajani on Clinical Implications of Trastuzumab Deruxtecan in Gastric and GEJ Adenocarcinoma

July 23rd 2020

Jaffer A. Ajani, MD, discusses the potential clinical implications of fam-trastuzumab deruxtecan-nxki in gastric or gastroesophageal junction adenocarcinoma if approved by the FDA.

Experts Highlight Promise of Trastuzumab Deruxtecan in Gastric/GEJ Cancers

July 21st 2020

Experts share their insight on the efficacy and safety of trastuzumab deruxtecan in the gastric cancer space.